Endovascular Recanalization for Acute Internal Carotid Artery Terminus Occlusion: A Subgroup Analysis From the Direct-MT Trial

BACKGROUND: The efficacy of endovascular recanalization for internal carotid artery (ICA) terminus occlusion has not been completely evaluated.

OBJECTIVE: To investigate the efficacy of endovascular recanalization for ICA terminus occlusion.

METHODS: Data from Direct-MT, a randomized controlled trial, were applied. ICA terminus occlusions were diagnosed with preprocedure computed tomography angiography by the core laboratory. We dichotomized the ICA terminus occlusions into 2 groups (non-T and T) and analyzed the differences between them. Single-factor analysis and multiple logistic regression were applied to detect independent factors for clinical outcomes and futile recanalization.

RESULTS: The rates of first-pass effect, successful recanalization, good clinical outcome, mortality, and futile recanalization were 22.3% (50 of 224), 83.0% (181 of 224), 24.6% (55 of 224), 26.7% (60 of 224), and 69.6% (126 of 181), respectively. Baseline National Institutes of Health Stroke Scale (negative factor; odds ratio [OR] 0.89; 95% CI 0.84-0.95; P < .001), hypertension (negative factor; OR 0.38; 95% CI 0.18-0.80; P = .010), Alberta Stroke Program Early CT Score ≥ 6 (OR 3.68; 95% CI 1.29-10.5; P = .014), tirofiban use (OR 2.46; 95% CI 1.16-5.19; P = .018), first-pass effect (OR 2.87; 95% CI 1.28-6.41; P = .010), and final extended thrombolysis in cerebral infarction ≥ 2b (OR, 3.50; 95% CI 1.17-10.4; P = .024) were independent factors for good clinical outcome. Baseline National Institutes of Health Stroke Scale (OR 1.12; 95% CI 1.05-1.20; P = .004), Alberta Stroke Program Early CT Score < 6 (OR 4.68; 95% CI 1.51-14.5; P = .007), tirofiban use (negative factor; OR 0.39; 95% CI 0.18-0.86; P = .020), and first-pass effect (negative factor; OR 0.44; 95% CI 0.19-0.99; P = .047) were independent factors for futile recanalization.

CONCLUSION: More efforts in modifiable factors should be made to improve the efficacy of endovascular recanalization for better clinical outcomes and less futile recanalization in ICA terminus occlusions.

KEY WORDS: Endovascular, Internal carotid artery, Terminus, Stroke, Thrombectomy

Acute internal carotid artery (ICA) terminus occlusion refers to vessel occlusion at the ICA terminal segment, with or without downstream flow disruption. ICA terminus occlusion has a poorer outcome as compared with occlusions of more distal vessels for its large clot burden and impairment in collaterals.1,2 Meanwhile, patients with ICA terminus occlusion were less likely to have favorable outcomes as compared with tandem occlusion and with ICA plus cerebral branch occlusions.3,4 However, the endovascular recanalization for ICA terminus occlusions have been reported by a few studies with only limited quantities.1,5-8

In recent years, several randomized controlled trials have verified the endovascular recanalization as a standard therapy for large vessel occlusions...
Successful recanalization (extended thrombolysis in cerebral infarction [eTICI] ≥ 2b) rates for LVOs have achieved great progress, but the 90-day clinical outcomes have not improved in keeping with the excellent reperfusion results. The concept of futile recanalization (unfavorable clinical outcome despite successful recanalization) is getting increased attention in the recent years, notwithstanding the paucity of data for acute ICA terminus occlusion.\textsuperscript{10}

Direct-MT was the first randomized controlled trial to prove the noninferiority of thrombectomy alone to thrombectomy with preceding intravenous thrombolysis for LVOs and included more than 200 ICA terminus occlusions.\textsuperscript{11} In this study, we conducted a subgroup analysis focusing on ICA terminus occlusions based on data from the Direct-MT trial. We described the characteristics of different occlusion morphologies and evaluated the independent factors for good clinical outcome, mortality, and futile recanalization to provide a reference to the efficacy of endovascular recanalization for acute ICA terminus occlusions.

**METHODS**

**Patient Sample**

The data of this study are available from the corresponding author upon reasonable request. Data from the Direct-MT trial were applied for this subgroup analysis. Patient eligibility and protocol of the Direct-MT trial (NCT03469206) have been reported previously.\textsuperscript{12} In this subgroup analysis, we only focused on patients with ICA terminus occlusion from the Direct-MT trial based on preprocedure computed tomography angiography (CTA), according to the core laboratory analysis. As for occlusion type, ICA terminus occlusions were dichotomized into 2 types: type non-T occlusion was defined as the occlusion involving (1) the terminal ICA alone or (2) either middle cerebral artery (MCA) or anterior cerebral artery (ACA) combined with the terminal ICA; type T occlusion was defined as occlusion involving the MCA, ACA, and terminal ICA simultaneously. This study was approved by all relevant local ethics committees and research boards. Written informed consent was obtained from all the patients or their legal representatives.

**Qualitative and Quantitative Assessment**

The collateral grading system was scored on a 4-point scale of 0 to 3. A score of 0 indicated no collateral. A score of 1 indicated collaterals filling ≤50% but >0% of the occluded territory. A score of 2 indicated collaterals filling >50% but <100% of the occluded territory. A score of 3 indicated collaterals filling 100% of the occluded territory.\textsuperscript{13} The extent of thrombus was quantified using the clot burden score.\textsuperscript{14} Successful reperfusion was defined as final eTICI 2b, 2c, or 3.\textsuperscript{15} The first-pass effect (FPE) was defined as achieving complete recanalization (eTICI3) with a single thrombectomy device pass.\textsuperscript{16} Symptomatic intracranial hemorrhage was defined according to the Heidelberg criteria.\textsuperscript{17} Perioperative complications included symptomatic intracranial hemorrhage and
asymptomatic intracranial hemorrhage, embolization into a new territory,\textsuperscript{18} infarction in new territory at 5 to 7 days, large or malignant MCA infarction, and any other procedural complications. The outcome lesion volume was assessed on follow-up CT on days 5 to 7 using an automated algorithm.\textsuperscript{19} Tirofiban was used as periprocedural transarterial and/or transvenous use of tirofiban, a nonpeptide selective glycoprotein IIb/IIIa receptor inhibitor, by operators based on their experience to eliminate clot growing or to achieve unavoidable emergent stent angioplasty.

### Outcomes of Interest

A good clinical outcome was defined as modified Rankin Scale (mRS) 0 to 2 at 90 days. Mortality was defined as an mRS score of 6 at 90 days. Futile recanalization was defined as 90-day mRS > 2 despite a final eTICI ≥ 2b.\textsuperscript{20,21}

### Statistical Analysis

Categorical variables were expressed as frequencies and percentages, continuous as mean (SD) for normal distribution or median (IQR) for non-normal distribution. Missing data were imputed with the use of multiple imputation by fully conditional specification regression for continuous variables or by fully conditional specification logistic regression for binary and ordinal variables. Categorical variables were tested using the $\chi^2$ test. Continuous variables with normal distribution were tested using the $t$ test. Continuous variables with non-normal distribution were tested using the rank sum test. Nonparametric testing of categorical variables was tested using the Fisher exact test. Statistical testing was conducted when variables related to good clinical outcome, mortality, and futile recanalization significantly in the single-factor analysis, $P<.05$. All the analyses were performed using the SAS software, version 9.2 (SAS Institute).

### RESULTS

#### Baseline Data and General Description for Acute ICA Terminus Occlusion in the Direct-MT Trial

There were 1586 patients screened for eligibility and 656 patients randomized. Of 656 patients, 327 patients allocated to the thrombectomy alone group and 329 patients to the combination therapy group. Then, 12 patients were excluded from the combination therapy group because of missing baseline CTA in 5 and absence of target artery occlusion in 7. Four patients were excluded from the combination therapy group because of missing baseline CTA in 3 and absence of target artery occlusion in 1. Finally, 224 patients met the criteria of ICA terminus occlusion based on core laboratory diagnosis, with 111 in the thrombectomy alone group and 113 in the combination therapy group. The flow diagram of patient selection is presented in Figure. The rates of first-pass effect, successful recanalization, good clinical outcome, mortality, and futile recanalization were 22.3% (50 of 224), 83.0% (181 of 224), 24.6% (55 of 224), 26.7% (60 of 224), and 69.6% (126 of 181), respectively. Relevant data are presented in Table 1. There was no difference between the thrombectomy alone group and combination therapy group in final eTICI ≥ 2b and 90-day mRS 0 to 2 (see Table S1 in Supplemental Digital Content, http://links.lww.com/NEU/D243).

### Analysis for ICA Terminus Occlusion Based on Occlusion Types

We dichotomized the acute ICA terminus occlusions into 2 types (non-T and T) and analyzed the differences between them. There were 39 ICA terminus occlusions for type non-T and 185 for type T. For the cause of stroke, the proportions of intracranial atherosclerosis and ipsilateral extracranial stenosis were higher in type non-T than in type T ($P<.001$). Clot burden score was 4 (2, 6) for type non-T vs 1 (1, 2) for type T ($P<.001$). Collateral score 0 to 1 was found in 90.2% for type T and 61.5% for type non-T ($P<.001$). The patency of anterior communicating artery was of no difference between 2 types ($P=.42$). The 24 to 72 h ASPECTS

| Variable                   | ICA terminus occlusion |
|----------------------------|------------------------|
| Overall, No.               | 224                    |
| Male                       | 125 (55.80%)           |
| Age, y; median (IQR)       | 70 (62.76)             |
| BMI, median (IQR)          | 22.86 (21.45, 25.47)   |
| Medical history            |                        |
| Atrial fibrillation        | 109 (48.66%)           |
| Hypertension               | 135 (60.27%)           |
| Diabetes mellitus          | 42 (18.75%)            |
| Hypercholesterolemia       | 8 (3.57%)              |
| Chronic heart failure      | 16 (7.14%)             |
| Smoking                    | 42 (18.75%)            |
| Cause of stroke            |                        |
| Cardioembolic              | 105 (46.88%)           |
| Intracranial atherosclerosis | 4 (1.79%)            |
| Ipsilateral extracranial stenosis | 30 (13.39%) |
| Undetermined               | 85 (37.95%)            |
| Baseline NIHSS, median (IQR) | 19 (15, 23)          |
| Baseline SBP, mmHg; median (IQR) | 145 (131, 160.5) |
| Baseline DBP, mmHg; median (IQR) | 84.5 (76, 93)   |
| Thrombectomy alone         | 111 (49.55%)           |
| First-pass effect          | 50 (22.3%)             |
| Final eTICI $^a$            |                        |
| ≥2b                        | 181 (83.03%)           |
| 3                          | 71 (31.70%)            |
| 90-d mRS 0-2               | 55 (24.66%)            |
| Mortality                  | 60 (26.79%)            |
| Futile recanalization $^b$ | 126 (69.6%)            |

BMI, body mass index; DBP, diastolic blood pressure; eTICI, extended thrombolysis in cerebral ischemia; ICA, internal carotid artery; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure.

$^a$Missing BMI (n = 3 in the thrombectomy group).

$^b$Missing final eTICI (n = 3 in the thrombectomy group).

$^c$Futile recanalization indicates 90-day mRS > 2 despite eTICI ≥ 2b.

Data are presented as No./total No. (%) unless otherwise stated. Mortality indicates 90-day mRS = 6.
was 5 (3, 8) for type non-T and 3 (1, 6) for type T ($P = .010$).

Outcome lesion volume was larger in type T than in type non-T (75.8 (21.9, 149.0) mL vs 24.9 (7.75, 67.1) mL, $P = .018$). The FPE%, rates of final eTICI ≥ 2b, good clinical outcome, and mortality were of no difference between type T and type non-T occlusion (Table 2). There was no difference in rates of final eTICI ≥ 2b, final eTICI3, first-pass effect, good clinical outcome, mortality, and symptomatic intracranial hemorrhage between 2 arms (mechanical thrombectomy vs intravenous thrombolysis plus mechanical thrombectomy) in either occlusion type (see Table S2 in Supplemental Digital Content, http://links.lww.com/NEU/D244).

### Factors for Clinical Outcomes of ICA Terminus Occlusions in the Direct-MT Trial

According to multiple logistic regression, baseline National Institutes of Health Stroke Scale (NIHSS; negative factor; OR 0.89; 95% CI 0.84-0.95; $P < .001$), hypertension (negative factor;...
OR 0.38; 95% CI 0.18-0.80; P = .010), ASPECTS ≥ 6 (OR 3.68; 95% CI 1.29-10.5; P = .014), tirofiban use (OR 2.46; 95% CI 1.16-5.19; P = .018), and final eTICI ≥ 2b (OR 3.50; 95% CI 1.17-10.4; P = .024) were independent factors for good clinical outcome. Meanwhile, baseline NIHSS (OR 1.05; 95% CI 1.01-1.11; P = .018), diabetes mellitus (negative factor; OR 0.32; 95% CI 0.15-0.69; P = .003), and collateral score 0 to 1 (OR 5.73; 95% CI 1.24-26.3; P = .024) were independent factors for mortality (Tables 3 and 4).

The futile recanalization rate for acute ICA terminus occlusion was 69.6% (126 of 181). Ninety-day mRS > 2 was observed in 67.6% (48 of 71) of patients despite final eTICI3. Baseline NIHSS (OR 1.12; 95% CI 1.05-1.11; P = .004), ASPECTS < 6 (OR 4.68; 95% CI 1.51-14.5; P = .007), tirofiban use (negative factor; OR 0.39; 95% CI 0.18-0.86; P = .020), and FPE (negative factor; OR 0.44; 95% CI 0.19-0.99; P = .047) were independent factors for futile recanalization. However, the collateral score 0 to 1 was not associated with futile recanalization (Table 5).

**DISCUSSION**

The main results of this subgroup analysis from the Direct-MT trial include that, for acute ICA terminus occlusions, (1) the futile recanalization rate reached 69.6%, (2) the first-pass effect, as an independent protective factor for good clinical outcome and futile recanalization elimination, was achieved in only 22.3% patients and warrants improvement, (3) and tirofiban use might be protective. These results provide insights into endovascular recanalization for acute ICA terminus occlusions.

Collateral flow can modify endovascular treatment efficacy by facilitating thrombus retrieval and lowering the number of device passes. In addition, under different collateral flows, even the association between the clot burden score and functional outcome

### TABLE 3. Factors Analysis for 90-Day mRS 0-2

| Variable                  | Single-factor analysis | Multiple logistic regression |
|---------------------------|------------------------|-----------------------------|
|                          | OR (95% CI)            | P value                     | OR (95% CI)            | P value |
| Baseline NIHSS            | 0.888 (0.838, 0.940)   | <.001                       | 0.896 (0.843, 0.952)   | .0004   |
| Male                      | 2.131 (1.162, 4.070)   | .0204                       |                            |         |
| Hypertension              | 0.498 (0.269, 0.922)   | .0253                       |                            |         |
| Diabetes mellitus         | 0.354 (0.132, 0.952)   | .0332                       |                            |         |
| Smoking                   | 2.241 (1.094, 4.587)   | .0250                       |                            |         |
| Cardioembolism            | 0.453 (0.239, 0.858)   | .0140                       |                            |         |
| ASPECTS ≥ 6               | 5.147 (1.763, 15.026)  | .0011                       | 3.686 (1.294, 10.500)    | .0146   |
| Collateral score 2-3      | 2.290 (1.052, 4.986)   | .0334                       |                            |         |
| Tirofiban use             | 2.264 (1.190, 4.307)   | .0116                       | 2.461 (1.166, 5.192)     | .0181   |
| First-pass effect, %      | 2.629 (1.136, 5.171)   | .0051                       | 2.871 (1.285, 6.414)     | .0101   |
| Final eTICI ≥ 2b          | 3.806 (1.109, 13.058)  | .0239                       | 3.500 (1.174, 10.437)    | .0246   |

ASPECTS, Alberta Stroke Program Early Computed Tomography score; eTICI, extended thrombolysis in cerebral ischemia; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio.

*Baseline NIHSS (median [IQR]) referred to 16 (12, 20) for patients with 90-day mRS 0-2 vs 20 (16, 24) for patients with 90-day mRS > 2.

### TABLE 4. Factors Analysis for 90-Day mRS 6

| Variable                  | Single-factor analysis | Multiple logistic regression |
|---------------------------|------------------------|-----------------------------|
|                          | OR (95% CI)            | P value                     | OR (95% CI)            | P value |
| Baseline NIHSS            | 1.060 (1.017, 1.106)   | .0059                       | 1.057 (1.009, 1.106)   | .0183   |
| Diabetes mellitus         | 0.352 (0.175, 0.709)   | .0027                       | 0.323 (0.151, 0.694)   | .0038   |
| Collateral score 0-1      | 6.759 (1.565, 29.185)  | .0036                       | 5.731 (1.246, 26.364)  | .0249   |
| Stent retriever first     | 0.259 (0.101, 0.661)   | .0028                       |                            |         |
| Final eTICI < 2b          | 2.439 (1.107, 5.372)   | .0239                       |                            |         |
| Symptomatic intracranial hemorrhage | 6.359 (2.076, 19.482) | .0009                       |                            |         |
| Hemicraniectomy           | 2.754 (1.059, 7.160)   | .0319                       |                            |         |
| Large or malignant MCA infarction | 10.799 (5.380, 21.677) | <.0001                     |                            |         |

eTICI, extended thrombolysis in cerebral ischemia; MCA, middle cerebral artery; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odds ratio.

*Baseline NIHSS (median [IQR]) referred to 22 (17, 25) for patients with 90-day mRS = 6 vs 18 (14, 22) for patients with 90-day mRS < 6.
It is rational to speculate that, especially for ICA terminus occlusion, heavy clot burdens and concurrent insufficient collateral flow are associated with poor clinical outcome. However, there was no difference in clinical outcome despite significant differences in the collateral status between the 2 occlusion types. The reason might be the comparable rates of the first-pass effect between 2 occlusion types.

The first-pass effect was first introduced to evaluate thrombectomy devices as a new metric in 354 patients from the North American Solitaire Acute Stroke Registry database. In Systematic Evaluation of Patients Treated with Stroke Devices for Acute Ischemic Stroke registry, FPE was demonstrated as a surrogate for superior clinical outcome. The FPE group in each registry had only 10.1% and 13.5% ICA terminus occlusions, less than the non-FPE group significantly. Moreover, the ICA terminus clot was considered a negative predictor of FPE. According to our data, although it was only achieved in 22.3% ICA terminus occlusions, FPE remained an independent factor for good clinical outcome and provided protection from futile recanalization. Recently, a large manually expandable stent retriever achieved 34.8% (8 of 23) of FPE in ICA terminus occlusion with successful recanalization in 95.7% (22 of 23) and mRS 0 to 2 in 26.1% (6 of 23) of patients. FPE, as a modifiable factor, warrants further improvements to achieve better clinical outcomes in thrombectomy for ICA terminus occlusions.

Futile recanalization refers to the absence of clinical improvement after successful endovascular recanalization. In one multicenter study, advanced age, higher baseline NIHSS score, delayed puncture to reperfusion, and use of general anesthesia were associated with a futile recanalization rate of 49.6%. In a prospective single-center registry, greater age, higher admission NIHSS score, and lower ASPECTS were predictors for 90-day mRS 3 to 6 despite final TICI3, which was observed in 54.5% of patients. In this subanalysis, higher baseline NIHSS and ASPECTS < 6 were independent risk factors for a futile recanalization rate of 69.6%. Recently, complete TICI 3 reperfusion was found to have greater functional outcomes than incomplete TICI 2b reperfusion in several studies. However, no substantial difference in the futile recanalization rate was detected between the final eTICI ≥ 2b group and final eTICI3 group according to our data (69.6% for the final eTICI ≥ 2b group vs 67.6% for the final eTICI3 group).

Tirofiban has been evaluated for its safety and efficacy in mechanical thrombectomy for LVOs, even in intravenous thrombolysis bridging. By local infusion alone or with subsequent intravenous infusion, rescue tirofiban use improved 90-day clinical outcome even at low dose. Given that tirofiban use might be protective in achieving good clinical outcome and eliminating futile recanalization, its in-depth value should be explored in the near future. However, no guideline or consensus is yet available to determine the occasion or accurate dosage for tirofiban use during thrombectomy.

**Limitations**

This subgroup analysis had limitations. First, in line with the Direct-MT trial design, all conclusions should be applied to acute ICA terminus occlusions treated within 4.5 hours after stroke onset and are not generalized to others later than the time window. Second, according to the protocol of the Direct-MT trial, the evaluation of vessel anatomy was based on preprocedure CTA. No further evaluation by contralateral injection was mandatory, considering the risk of reperfusion delay. Actually, we are unable to exclude the situation that the deficiency of ipsilateral A1 segment as the consequence of the anatomic absence rather than the pathologic occlusion, which might overestimate the T occlusion in this analysis. However, we further evaluated the patency of anterior communicating artery on preprocedure CTA in all patients and found no difference between 2 occlusion groups. It might provide indirect support that the differences detected in variables in this analysis reflected, to some extent, the inherent discrepancy between 2 occlusion morphologies. Third, although tirofiban use might be protective, it was given based on operator experience instead of guidelines or consensus instructions. Further studies should be designed to explore the standard use of tirofiban in ICA terminus clot thrombectomy. Fourth, the number of patients of each preferred first strategy (with stent retriever vs with...
aspiration) differed widely. Thus, the efficacy of each strategy in the first attempt to complete recanalization is not comparable. Fifth, given the nature of this subgroup analysis, the independent factors provided may not have the power to predict clinical outcomes. More specifically designed studies should be conducted to address these issues.

**CONCLUSION**

For acute ICA terminus occlusion, the successful recanalization is unable to ensure compatible good clinical outcomes, and the issues of futile recanalization remain unresolved. More efforts, especially in the modifiable factors, should be made to improve the efficacy of endovascular recanalization for the purpose of better clinical outcomes and less futile recanalization.

**Funding**

This study did not receive any funding or financial support.

**Disclosures**

The authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article.

**REFERENCES**

1. Liebeskind DS, Flint AC, Budzik RF, et al Carotid I’s, L’s and T’s: collaterals shape the outcome of intracranial carotid occlusion in acute ischemic stroke. J Neurointerv Surg. 2015;7(6):402-407.
2. Barreto AD, Albright KC, Hallevi H, et al Thrombus burden is associated with clinical outcome after intra-arterial therapy for acute stroke. Stroke. 2008;39(12):3231-3235.
3. Fischer U, Mono ML, Schroth G, et al Endovascular therapy in 201 patients with acute symptomatic occlusion of the internal carotid artery. Eur J Neurol. 2013;20(7):1017-1024; e1087.
4. Saqqur M, Uchino K, Demchuk AM, et al Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007;38(5):948-954.
5. Ou T, Shigera K, Amano T, Kaneko J. Endovascular treatment for acute carotid T and carotid non-T occlusion: a retrospective multicentre study of 81 patients. Interv Neuroradiol. 2019;25(5):497-501.
6. Bradas GB, Venturi F, Stura G, et al Considerations about occlusion of the intracranial distal internal carotid artery. Clin Neuroradiol. 2017;27(2):169-174.
7. Flint AC, Duckwiler GR, Budzik RF, Liebeskind DS, Smith WS Mechanical thrombectomy of intracranial internal carotid occlusion: pooled results of the MERCI and multi MERCI Part I trials. Stroke. 2007;38(4):1274-1280.
8. Bourcier R, Alexandre PL, Eugene F, et al Is bridging therapy still required in stroke due to carotid artery terminus occlusion? J Neurointerv Surg. 2018;10(7):625-628.
9. Goyal M, Menon BK, van Zwam WH, et al Endovascular thrombectomy after large-vessel ischemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723-1731.
10. Hussein HM, Georgiadis AL, Vazquez G, et al Occurrence and predictors of futile recanalization following endovascular treatment among patients with acute ischemic stroke: a multicenter study. AJNR Am J Neuroradiol. 2010;31(3):454-458.
11. Yang P, Zhang Y, Zhang L, et al Endovascular thrombectomy with or without Intravenous Alteplase in acute stroke. N Engl J Med. 2020;382(21):1981-1993.
12. Yang P, Treurniet KM, Zhang L, et al Direct Intr-arterial thrombectomy in order to revascularize AIS patients with large vessel occlusion Efficiently in Chinese Tertiary hospitals: a Multicenter randomized clinical Trial (DIRECT-MT)-Protocol. Int J Stroke. 2020;15(6):689-698.
13. Tan YJ, Demchuk AM, Hopyan J, et al CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarcts. AJNR Am J Neuroradiol. 2009;30(3):525-531.
14. Puetz V, Dzialowski I, Hill MD, et al Intracranial thrombus extent predicts clinical outcome, final infarct size and hemorrhagic transformation in ischemic stroke: the clot burden score. Int J Stroke. 2008;3(4):230-236.
15. Goyal M, Fargen KM, Turk AS, et al 2C or not 2C: defining an improved revascularization grading scale and the need for standardization of angiography outcomes in stroke trials. J Neurointerv Surg. 2014;6(2):83-86.
16. Zaidat OO, Castanga UC, Linfante I, et al First pass effect: a new measure for stroke thrombectomy devices. Stroke. 2018;49(3):660-666.
17. von Kummer R, Broderick JP, Campbell BC, et al The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015;46(10):2981-2986.
18. Goyal M, Menon BK, Demchuk A, et al Proposed methodology and classification of Infarct in New Territory (INT) after endovascular stroke treatment. J Neurointerv Surg. 2017;9(5):449-450.
19. Boers AM, Manquering HA, Jochem JJ, et al Automated cerebral infarct volume measurement in follow-up noncontrast CT scans of patients with acute ischemic stroke. AJNR Am J Neuroradiol. 2013;34(8):1522-1527.
20. Molina CA. Futility recanalization in mechanical embolectomy trials: a call to improve selection of patients for revascularization. Stroke. 2010;41(5):842-843.
21. Pedraza MI, de Lera M, Bos D, et al Brain Atrophy and the risk of futile endovascular reperfusion in acute ischemic stroke. Stroke. 2020;51(5):1514-1521.
22. Garcia-Tornel A, Ciollé L, Rubiera M, et al Leptomeningeal collateral flow modifies endovascular treatment efficacy on large-vessel occlusion strokes. Stroke. 2020; 52(1):299-303.
23. Derrazi I, Pou M, Labreuche J, et al Clot burden score and collateral status and their impact on functional outcome in acute ischemic stroke. AJNR Am J Neuroradiol. 2020;42(1):42-48.
24. JadHAV AP, Desai SM, Zaidat OO, et al First pass effect with neurothrombectomy for acute ischemic stroke: analysis of the systematic evaluation of patients treated with stroke devices for acute ischemic stroke registry. Stroke. 2021;53(3):e30-e32.
25. Maas V, Huisken S, Kalousek V, et al Mechanical thrombectomy in acute terminal internal carotid artery occlusions using a large manually expandable stentretriever (Tiger XL Device): multicenter initial experience. J Clin Med. 2021;10(17):3853.
26. Back JH, Kim BM, Hoo JH, et al Number of stent retriever passes associated with futile recanalization in acute stroke. Stroke. 2018;49(9):2088-2095.
27. Xu H, Jia B, Huo X, et al Predictors of futile recanalization after endovascular treatment in patients with acute ischemic stroke in a multicenter registry study. J Stroke Cerebrovasc Dis. 2020;29(10):105067.
28. van Horn N, Kniep H, Leischner H, et al Predictors of poor clinical outcome despite complete reperfusion in acute ischemic stroke patients. J Neurosurg Surg. 2021;13(1):14-18.
29. Riva A, Seyedsaadat SM, Murad MH, et al Redefining 'success': a systematic review and meta-analysis comparing outcomes between incomplete and complete revascularization. J Neurointerv Surg. 2019;11(1):9-13.
30. Goyal M, Tsivgoulis G, Frei D, et al Comparative safety and efficacy of modified TICI 2b and TICI 3 reperfusion in acute ischemic strokes treated with mechanical thrombectomy. Neuroangiography. 2019;84(3):680-686.
31. Hua X, Yang M, Ma N, et al Safety and efficacy of tirofiban during mechanical thrombectomy for stroke patients with preceding intravenous thrombolysis. Clin Interv Aging. 2020;15:1241-1248.
32. Kim YW, Sohn SI, Yoo J, et al Local tirofiban infusion for remnant stenosis in large vessel occlusion: tirofiban ASSIST study. BMC Neuro. 2020;20(1):284.
33. Yang M, Hua X, Gao F, et al Low-dose rescue tirofiban in mechanical thrombectomy for acute cerebral large-artery occlusion. Eur J Neurol. 2020;27(6):1056-1061.

Supplemental digital content is available for this article at neurosurgery-online.com.

Supplemental Digital Content 1. Table S1. Comparison between the thrombectomy alone group and combination therapy group in baseline data and clinical outcomes.

Supplemental Digital Content 2. Table S2. Comparison between the 2 arms (mechanical thrombectomy vs intravenous thrombolysis plus mechanical thrombectomy) of either occlusion type.
COMMENT

The authors have submitted a manuscript exploring endovascular treatment of acute ICA terminus occlusions from a subset of the previously performed Direct-MT trial. The authors examined the 224 patients with an acute ICA terminus occlusion in this study and dichotomized them to 2 types (occlusions involving the terminal ICA alone or a combination of the ICA terminus and ACA or MCA). The results of this analysis demonstrated that ICA occlusions suffer from poor clinical outcomes despite a high percentage of successful recanalization (83%) observed. The authors mention this in the context of known low first pass effect when performing thrombectomy for ICA terminus occlusions. The results from this current analysis demonstrating the difficult nature of thrombectomy for ICA terminus occlusions serve as a view of where we can continue to advance the field of endovascular neurosurgery. New device development and the advent of novel techniques or protocols offer promise in addressing these challenges. The Direct-MT trial was performed with stent retrievers used as the primary option for thrombectomy based on 2015 AHA/ASA guidelines, with aspiration devices as a secondary option. Recent evidence from the Compass Trial demonstrates non-inferiority of direct aspiration as a first pass thrombectomy technique, however the current study only utilized aspiration first in 7 patients. As we continue to expand our ability to treat large-vessel occlusions and address increasingly complex challenges, studies such as this current one are necessary to highlight where we as a field should direct our focus.

Trevor Hardigan MD, PhD
Jay U. Howington MD
Savannah, Georgia, USA

1a. Turk AS 3rd, Siddiqui A, et al. Aspiration thrombectomy versus stent retriever thrombectomy as first-line approach for large vessel occlusion (COMPASS): a multicentre, randomised, open label, blinded outcome, non-inferiority trial. Lancet. 2019;393(10175):998-1008.